Burning Rock Biotech (BNR) Competitors $17.51 +0.81 (+4.85%) As of 12:35 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BNR vs. LMRI, CSTL, MCTA, FLGT, and TOIShould you buy Burning Rock Biotech stock or one of its competitors? MarketBeat compares Burning Rock Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Burning Rock Biotech include Lumexa Imaging (LMRI), Castle Biosciences (CSTL), Charming Medical (MCTA), Fulgent Genetics (FLGT), and Oncology Institute (TOI). These companies are all part of the "healthcare" industry. BNR vs. LMRIBNR vs. CSTLBNR vs. MCTABNR vs. FLGTBNR vs. TOIHow does Burning Rock Biotech compare to Lumexa Imaging?Lumexa Imaging (NASDAQ:LMRI) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings. Does the media prefer LMRI or BNR? In the previous week, Lumexa Imaging had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for Lumexa Imaging and 0 mentions for Burning Rock Biotech. Lumexa Imaging's average media sentiment score of 0.25 beat Burning Rock Biotech's score of 0.00 indicating that Lumexa Imaging is being referred to more favorably in the media. Company Overall Sentiment Lumexa Imaging Neutral Burning Rock Biotech Neutral Do analysts prefer LMRI or BNR? Lumexa Imaging currently has a consensus price target of $16.00, suggesting a potential upside of 101.94%. Given Lumexa Imaging's stronger consensus rating and higher possible upside, equities analysts plainly believe Lumexa Imaging is more favorable than Burning Rock Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lumexa Imaging 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has stronger earnings & valuation, LMRI or BNR? Lumexa Imaging has higher revenue and earnings than Burning Rock Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLumexa Imaging$1.03B0.74N/AN/AN/ABurning Rock Biotech$77.16M2.39-$7.92M-$0.79N/A Is LMRI or BNR more profitable? Lumexa Imaging has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -10.27%. Lumexa Imaging's return on equity of 0.00% beat Burning Rock Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Lumexa ImagingN/A N/A N/A Burning Rock Biotech -10.27%-9.98%-6.69% Do insiders & institutionals hold more shares of LMRI or BNR? 30.0% of Burning Rock Biotech shares are held by institutional investors. 0.7% of Lumexa Imaging shares are held by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryLumexa Imaging beats Burning Rock Biotech on 10 of the 13 factors compared between the two stocks.How does Burning Rock Biotech compare to Castle Biosciences?Burning Rock Biotech (NASDAQ:BNR) and Castle Biosciences (NASDAQ:CSTL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Which has higher earnings & valuation, BNR or CSTL? Burning Rock Biotech has higher earnings, but lower revenue than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Burning Rock Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBurning Rock Biotech$77.16M2.39-$7.92M-$0.79N/ACastle Biosciences$344.23M1.78-$24.16M-$0.44N/A Do analysts prefer BNR or CSTL? Castle Biosciences has a consensus price target of $45.33, suggesting a potential upside of 123.92%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Burning Rock Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Castle Biosciences 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Does the media refer more to BNR or CSTL? In the previous week, Castle Biosciences had 2 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for Castle Biosciences and 0 mentions for Burning Rock Biotech. Castle Biosciences' average media sentiment score of 1.39 beat Burning Rock Biotech's score of 0.00 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Burning Rock Biotech Neutral Castle Biosciences Positive Do institutionals and insiders have more ownership in BNR or CSTL? 30.0% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 30.3% of Burning Rock Biotech shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, BNR or CSTL? Burning Rock Biotech has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Is BNR or CSTL more profitable? Castle Biosciences has a net margin of -3.78% compared to Burning Rock Biotech's net margin of -10.27%. Castle Biosciences' return on equity of -2.77% beat Burning Rock Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Burning Rock Biotech-10.27% -9.98% -6.69% Castle Biosciences -3.78%-2.77%-2.30% SummaryCastle Biosciences beats Burning Rock Biotech on 12 of the 17 factors compared between the two stocks.How does Burning Rock Biotech compare to Charming Medical?Burning Rock Biotech (NASDAQ:BNR) and Charming Medical (NASDAQ:MCTA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership. Do analysts prefer BNR or MCTA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Charming Medical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has stronger valuation and earnings, BNR or MCTA? Charming Medical has lower revenue, but higher earnings than Burning Rock Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBurning Rock Biotech$77.16M2.39-$7.92M-$0.79N/ACharming MedicalN/AN/AN/AN/AN/A Is BNR or MCTA more profitable? Charming Medical has a net margin of 0.00% compared to Burning Rock Biotech's net margin of -10.27%. Charming Medical's return on equity of 0.00% beat Burning Rock Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Burning Rock Biotech-10.27% -9.98% -6.69% Charming Medical N/A N/A N/A Do institutionals & insiders believe in BNR or MCTA? 30.0% of Burning Rock Biotech shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer BNR or MCTA? In the previous week, Charming Medical had 5 more articles in the media than Burning Rock Biotech. MarketBeat recorded 5 mentions for Charming Medical and 0 mentions for Burning Rock Biotech. Charming Medical's average media sentiment score of 0.09 beat Burning Rock Biotech's score of 0.00 indicating that Charming Medical is being referred to more favorably in the news media. Company Overall Sentiment Burning Rock Biotech Neutral Charming Medical Neutral SummaryCharming Medical beats Burning Rock Biotech on 5 of the 8 factors compared between the two stocks.How does Burning Rock Biotech compare to Fulgent Genetics?Burning Rock Biotech (NASDAQ:BNR) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability. Is BNR or FLGT more profitable? Burning Rock Biotech has a net margin of -10.27% compared to Fulgent Genetics' net margin of -23.04%. Fulgent Genetics' return on equity of -3.24% beat Burning Rock Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Burning Rock Biotech-10.27% -9.98% -6.69% Fulgent Genetics -23.04%-3.24%-2.97% Which has more risk & volatility, BNR or FLGT? Burning Rock Biotech has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Fulgent Genetics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Do institutionals and insiders believe in BNR or FLGT? 30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 48.1% of Fulgent Genetics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 36.2% of Fulgent Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to BNR or FLGT? In the previous week, Fulgent Genetics had 4 more articles in the media than Burning Rock Biotech. MarketBeat recorded 4 mentions for Fulgent Genetics and 0 mentions for Burning Rock Biotech. Fulgent Genetics' average media sentiment score of 0.33 beat Burning Rock Biotech's score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the news media. Company Overall Sentiment Burning Rock Biotech Neutral Fulgent Genetics Neutral Which has stronger earnings and valuation, BNR or FLGT? Burning Rock Biotech has higher earnings, but lower revenue than Fulgent Genetics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBurning Rock Biotech$77.16M2.39-$7.92M-$0.79N/AFulgent Genetics$322.67M1.59-$60.51M-$2.39N/A Do analysts recommend BNR or FLGT? Fulgent Genetics has a consensus target price of $27.00, indicating a potential upside of 56.66%. Given Fulgent Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Burning Rock Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Fulgent Genetics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 SummaryFulgent Genetics beats Burning Rock Biotech on 11 of the 16 factors compared between the two stocks.How does Burning Rock Biotech compare to Oncology Institute?Burning Rock Biotech (NASDAQ:BNR) and Oncology Institute (NASDAQ:TOI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk. Is BNR or TOI more profitable? Oncology Institute has a net margin of -7.42% compared to Burning Rock Biotech's net margin of -10.27%. Oncology Institute's return on equity of 0.00% beat Burning Rock Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Burning Rock Biotech-10.27% -9.98% -6.69% Oncology Institute -7.42%N/A -24.68% Which has more volatility and risk, BNR or TOI? Burning Rock Biotech has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Do insiders and institutionals believe in BNR or TOI? 30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer BNR or TOI? In the previous week, Oncology Institute had 8 more articles in the media than Burning Rock Biotech. MarketBeat recorded 8 mentions for Oncology Institute and 0 mentions for Burning Rock Biotech. Oncology Institute's average media sentiment score of 1.46 beat Burning Rock Biotech's score of 0.00 indicating that Oncology Institute is being referred to more favorably in the news media. Company Overall Sentiment Burning Rock Biotech Neutral Oncology Institute Positive Which has higher earnings and valuation, BNR or TOI? Burning Rock Biotech has higher earnings, but lower revenue than Oncology Institute. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBurning Rock Biotech$77.16M2.39-$7.92M-$0.79N/AOncology Institute$502.73M0.82-$60.61M-$0.37N/A Do analysts rate BNR or TOI? Oncology Institute has a consensus price target of $7.00, indicating a potential upside of 67.75%. Given Oncology Institute's stronger consensus rating and higher possible upside, analysts clearly believe Oncology Institute is more favorable than Burning Rock Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Oncology Institute 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryOncology Institute beats Burning Rock Biotech on 11 of the 16 factors compared between the two stocks. Get Burning Rock Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for BNR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BNR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BNR vs. The Competition ExportMetricBurning Rock BiotechTechnology Services IndustryBusiness SectorNASDAQ ExchangeMarket Cap$184.21M$3.97B$6.57B$12.24BDividend YieldN/A2.22%3.07%5.36%P/E Ratio-22.1647.7929.3825.33Price / Sales2.3948.11397.6171.73Price / CashN/A38.4122.9355.00Price / Book2.415.286.766.97Net Income-$7.92M$31.26M$205.70M$334.92M7 Day Performance-5.66%-2.14%-1.73%-1.12%1 Month Performance-15.21%-4.07%-4.02%0.32%1 Year Performance464.84%30.87%32.52%33.28% Burning Rock Biotech Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BNRBurning Rock Biotech1.0694 of 5 stars$17.51+4.9%N/A+479.6%$184.21M$77.16MN/A1,390Positive NewsGap DownLMRILumexa Imaging3.6679 of 5 stars$7.00+3.4%$19.00+171.5%N/A$650.47M$267.73MN/A4,335Analyst ForecastHigh Trading VolumeCSTLCastle Biosciences3.7871 of 5 stars$19.20-0.6%$44.57+132.1%+21.4%$585.97M$344.23MN/A540MCTACharming MedicalN/A$29.36+6.8%N/AN/A$497.21MN/AN/A49Gap DownHigh Trading VolumeFLGTFulgent Genetics3.0362 of 5 stars$15.95+0.6%$27.00+69.3%-22.7%$471.50M$322.67MN/A1,315 Related Companies and Tools Related Companies Lumexa Imaging Competitors Castle Biosciences Competitors Charming Medical Competitors Fulgent Genetics Competitors Oncology Institute Competitors Viemed Healthcare Competitors Auna Competitors AirSculpt Technologies Competitors SBC Medical Group Competitors LifeMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BNR) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Burning Rock Biotech Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Burning Rock Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
